About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Biomea Fusion (NASDAQ: BMEA) Reports Positive Initial Findings From the COVALENT-111 Phase II Study of BMF-219 for the Treatment of Type 2 Diabetes

Biomea Fusion, Inc. (NASDAQ: BMEA) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, discovery and development of novel covalent small molecules to treat various types of metabolic diseases and cancers. Shares of the biopharma company are surging 69% through early trading on Tuesday, March 28, 2023. Over the past three months, Biomea Fusion has seen average daily volume of 106,890 shares. However, volume of 9.24 million shares or dollar volume of around $236.54 million, has already exchanged hands through early trading.

Shares of Biomea Fusion are soaring after the company revealed positive initial results for the first two patient cohorts suffering from type 2 diabetes mellitus (T2DM) who participated in the Phase II segment of their ongoing Phase I/II trial (COVALENT-111) featuring BMF-219, their exciting novel covalent menin inhibitor. After four weeks of daily 100 mg doses of BMF-219, Cohort 3 experienced an impressive A1c reduction, with 89% seeing a drop, 78% achieving a minimum 0.5% reduction, and a whopping 56% achieving an impressive 1% drop.

The Beta cell loss associated with both Type 2 and Type 1 Diabetes is a critical factor in the development and progression of the disease. Menin, in particular, has been identified as a primary inhibitor of Beta cell regeneration and recovery. That’s why Biomea created BMF-219 – a groundbreaking solution specifically designed to inhibit menin, thus taking the brakes off Beta cell restoration and allowing for their reactivation and preservation. For the first time, clinical observations of patients with diabetes have uncovered an impressive glucose-lowering effect induced by a novel menin inhibitor with a possible disease-altering mechanism of action. This could lead to sustained glycemic control even after treatment cessation.

Dr. Jose E. Rodriguez, a treating physician in COVALENT-111, stated that his patients experienced great benefits from being included in the study, with hardly any side effects and easy acceptance. Patients have seen positive health improvements, feeling better overall, happier, and more energetic than before they started the study. Further analysis and a detailed data summary will be presented at an upcoming major medical meeting.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Biomea Fusion (NASDAQ: BMEA) Reports Positive Initial Findings From the COVALENT-111 Phase II Study of BMF-219 for the Treatment of Type 2 Diabetes appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.